Compare SMWB & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMWB | PLYX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.7M | 114.1M |
| IPO Year | 2021 | N/A |
| Metric | SMWB | PLYX |
|---|---|---|
| Price | $2.58 | $4.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $8.13 | ★ $10.00 |
| AVG Volume (30 Days) | 1.7M | ★ 3.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.11 | N/A |
| Revenue Next Year | $11.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.22 | $2.20 |
| 52 Week High | $10.75 | $8.15 |
| Indicator | SMWB | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 27.07 | 48.51 |
| Support Level | $2.46 | $2.44 |
| Resistance Level | $7.83 | $5.05 |
| Average True Range (ATR) | 0.20 | 0.74 |
| MACD | 0.11 | 0.38 |
| Stochastic Oscillator | 23.58 | 44.49 |
Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.